{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:31:53Z","timestamp":1788535913878,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Oakland University Research Excellence Fund"},{"name":"NSF","award":["DMS-1122290"],"award-info":[{"award-number":["DMS-1122290"]}]},{"name":"NIH","award":["AI028433"],"award-info":[{"award-number":["AI028433"]}]},{"name":"NIH","award":["AI07881"],"award-info":[{"award-number":["AI07881"]}]},{"name":"NIH","award":["OD011095"],"award-info":[{"award-number":["OD011095"]}]},{"name":"HL","award":["109334"],"award-info":[{"award-number":["109334"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mathematical Biosciences"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.mbs.2013.04.012","type":"journal-article","created":{"date-parts":[[2013,5,16]],"date-time":"2013-05-16T10:02:35Z","timestamp":1368698555000},"page":"22-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents"],"prefix":"10.1016","volume":"245","author":[{"given":"Libin","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Perelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mbs.2013.04.012_b0005","unstructured":"World Health Organization. Hepatitis C. Fact sheet No. 164. Revised June 2011. <http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/index.html>."},{"issue":"Suppl. 2","key":"10.1016\/j.mbs.2013.04.012_b0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-2004-832934","article-title":"Past, present, and future hepatitis C treatments","volume":"24","author":"Foster","year":"2004","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.mbs.2013.04.012_b0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev-med-042010-085715","article-title":"Novel therapies for hepatitis C: insights from the structure of the virus","volume":"63","author":"Fusco","year":"2012","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.mbs.2013.04.012_b0020","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMe0901869","article-title":"A step forward in therapy for hepatitis C","volume":"360","author":"Hoofnagle","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.mbs.2013.04.012_b0025","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1053\/j.gastro.2007.03.116","article-title":"The hepatitis C virus life cycle as a target for new antiviral therapies","volume":"132","author":"Pawlotsky","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mbs.2013.04.012_b0030","first-page":"117","article-title":"New insights into HCV replication: potential antiviral targets","volume":"19","author":"Rice","year":"2011","journal-title":"Top Antivir. Med."},{"key":"10.1016\/j.mbs.2013.04.012_b0035","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2893.2012.01617.x","article-title":"Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents","volume":"19","author":"Poordad","year":"2012","journal-title":"J. Viral Hepat."},{"issue":"Suppl. 1","key":"10.1016\/j.mbs.2013.04.012_b0040","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0168-8278(12)60010-5","article-title":"Antiviral strategies in hepatitis C virus infection","volume":"56","author":"Sarrazin","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mbs.2013.04.012_b0045","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.mbs.2013.04.012_b0050","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jhep.2011.01.046","article-title":"Antiviral activity, safety, and pharmacokinetics of danoprevir\/ritonavir plus PEG-IFN alpha-2a\/RBV in hepatitis C patients","volume":"55","author":"Gane","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mbs.2013.04.012_b0055","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/infdis\/jir315","article-title":"Antiviral activity of danoprevir (ITMN-191\/RG7227) in combination with pegylated interferon alpha-2a and ribavirin in patients with hepatitis C","volume":"204","author":"Forestier","year":"2011","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.mbs.2013.04.012_b0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2011.05.014","article-title":"Second-wave protease inhibitors: choosing an heir","volume":"15","author":"Ciesek","year":"2011","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.mbs.2013.04.012_b0065","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2012.02.015","article-title":"Anti-hepatitis C virus drugs in development","volume":"142","author":"Schaefer","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mbs.2013.04.012_b0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1177\/135965350000500203","article-title":"Hepatitis C virus kinetics","volume":"5","author":"Herrmann","year":"2000","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.mbs.2013.04.012_b0075","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1365-2893.2010.01348.x","article-title":"A perspective on modelling hepatitis C virus infection","volume":"17","author":"Guedj","year":"2010","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.mbs.2013.04.012_b0080","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1615\/CritRevImmunol.v30.i2.30","article-title":"Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling","volume":"30","author":"Rong","year":"2010","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.mbs.2013.04.012_b0085","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"Neumann","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.mbs.2013.04.012_b0090","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1053\/jhep.2002.32672","article-title":"Mechanism of action of ribavirin in the combination treatment of chronic HCV infection","volume":"35","author":"Lau","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.mbs.2013.04.012_b0095","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1053\/j.gastro.2003.12.002","article-title":"Antiviral action of ribavirin in chronic hepatitis C","volume":"126","author":"Pawlotsky","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mbs.2013.04.012_b0100","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1053\/jhep.2003.50218","article-title":"Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon","volume":"37","author":"Herrmann","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.mbs.2013.04.012_b0105","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.mbs.2013.04.012_b0110","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1053\/jhep.2003.50217","article-title":"Viral dynamics and response differences in HCV-infected african american and white patients treated with IFN and ribavirin","volume":"37","author":"Layden-Almer","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.mbs.2013.04.012_b0115","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jtbi.2010.08.036","article-title":"Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics","volume":"267","author":"Guedj","year":"2010","journal-title":"J. Theor. Biol."},{"key":"10.1016\/j.mbs.2013.04.012_b0120","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"Guedj","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mbs.2013.04.012_b0125","doi-asserted-by":"crossref","first-page":"e1002959","DOI":"10.1371\/journal.pcbi.1002959","article-title":"Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model","volume":"9","author":"Rong","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.mbs.2013.04.012_b0130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3934\/mbe.2004.1.267","article-title":"An age-structured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells","volume":"1","author":"Nelson","year":"2004","journal-title":"Math. Biosci. Eng."},{"key":"10.1016\/j.mbs.2013.04.012_b0135","first-page":"87","article-title":"Mathematical modeling of HIV-1 infection and drug therapy","author":"Rong","year":"2008"},{"key":"10.1016\/j.mbs.2013.04.012_b0140","series-title":"Volterra Integral and Functional Equations","author":"Gripenberg","year":"1990"},{"key":"10.1016\/j.mbs.2013.04.012_b0145","first-page":"1035","article-title":"Semiflows generated by Lipschitz perturbations of non-densely defined operators","volume":"3","author":"Thieme","year":"1990","journal-title":"Differ. Integral Equ."},{"key":"10.1016\/j.mbs.2013.04.012_b0150","author":"Webb","year":"1985"},{"key":"10.1016\/j.mbs.2013.04.012_b0155","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1137\/0153068","article-title":"How may infection-age-dependent infectivity affect the dynamics of HIV\/AIDS?","volume":"53","author":"Thieme","year":"1993","journal-title":"SIAM J. Appl. Math."},{"key":"10.1016\/j.mbs.2013.04.012_b0160","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1137\/S003613990038205X","article-title":"A two-strain TB model with age-structure","volume":"62","author":"Feng","year":"2002","journal-title":"SIAM J. Appl. Math."},{"key":"10.1016\/j.mbs.2013.04.012_b0165","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1137\/060663945","article-title":"Mathematical analysis of age-structured HIV-1 dynamics with combination antiretroviral therapy","volume":"67","author":"Rong","year":"2007","journal-title":"SIAM J. Appl. Math."},{"key":"10.1016\/j.mbs.2013.04.012_b0170","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1128\/AAC.48.12.4784-4792.2004","article-title":"Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells","volume":"48","author":"Lin","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.mbs.2013.04.012_b0175","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1073\/pnas.1100349108","article-title":"Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy","volume":"108","author":"Hsu","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mbs.2013.04.012_b0180","doi-asserted-by":"crossref","first-page":"E302","DOI":"10.1073\/pnas.1104149108","article-title":"Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy","volume":"108","author":"Guedj","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.mbs.2013.04.012_b0185","doi-asserted-by":"crossref","first-page":"30ra32","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"Rong","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mbs.2013.04.012_b0190","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s11538-012-9736-y","article-title":"Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor","volume":"74","author":"Rong","year":"2012","journal-title":"Bull. Math. Biol."},{"key":"10.1016\/j.mbs.2013.04.012_b0195","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration","volume":"53","author":"Guedj","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.mbs.2013.04.012_b0200","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jhep.2011.12.012","article-title":"Understanding silibinin\u2019s modes of action against HCV using viral kinetic modeling","volume":"56","author":"Guedj","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.mbs.2013.04.012_b0205","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.24788","article-title":"Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine","volume":"55","author":"Guedj","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.mbs.2013.04.012_b0210","doi-asserted-by":"crossref","first-page":"e1000745","DOI":"10.1371\/journal.pcbi.1000745","article-title":"A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants","volume":"6","author":"Adiwijaya","year":"2010","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.mbs.2013.04.012_b0215","doi-asserted-by":"crossref","first-page":"e1002339","DOI":"10.1371\/journal.pcbi.1002339","article-title":"A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection","volume":"8","author":"Adiwijaya","year":"2012","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.mbs.2013.04.012_b0220","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s11901-011-0101-7","article-title":"Hepatitis C viral kinetics in the era of direct acting antiviral agents and IL28B","volume":"10","author":"Dahari","year":"2011","journal-title":"Curr. Hepat. Rep."},{"key":"10.1016\/j.mbs.2013.04.012_b0225","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.3851\/IMP2428","article-title":"Mathematical modeling of HCV infection: what can it teach us in the era of direct antiviral agents?","volume":"17","author":"Chaterjee","year":"2012","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.mbs.2013.04.012_b0230","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cld.2012.09.003","article-title":"Hepatitis C viral kinetics: the past, present and future","volume":"17","author":"Chaterjee","year":"2013","journal-title":"Clin. Liver Dis."}],"container-title":["Mathematical Biosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556413001223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025556413001223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T20:32:00Z","timestamp":1715373120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025556413001223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0025556413001223"],"URL":"https:\/\/doi.org\/10.1016\/j.mbs.2013.04.012","relation":{},"ISSN":["0025-5564"],"issn-type":[{"value":"0025-5564","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents","name":"articletitle","label":"Article Title"},{"value":"Mathematical Biosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mbs.2013.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}